Moorthy Palanki’s Post

Private biotech funding rises as venture firms deploy cash https://lnkd.in/g75yvCQp Private funding for biotechnology startups rose during the first three months of the year, suggesting some of the sector’s momentum has translated to stepped-up investment in young drugmakers. Twenty-six companies closed private fundraising rounds worth [...]

New insight from BioPharma Dive, highlighting a significant uptick in venture capital funding for biotech companies during the first quarter of 2024. This surge in investment underscores the growing confidence in the potential of the biotech sector to drive innovation and address pressing healthcare challenges. As we witness this positive momentum in biotech funding, it's evident that investors are recognizing the value and potential returns associated with supporting advancements in the life sciences. This influx of capital will undoubtedly fuel further innovation and accelerate the development of novel treatments and solutions. #Biotech #VentureCapital #Innovation #Healthcare #Investment #FutureofMedicine

Private #biotech funding rises as venture firms deploy cash! 26 companies closed private fundraising rounds worth more than $100 million in the first quarter, according to data from HSBC Innovation Banking shared with BioPharma Dive. While venture rounds have grown in size in recent years, $100 million is typically viewed as a significant threshold. 8 of those 26 biotechs were #cancer drugmakers, while 5 were startups developing programs for #neurological conditions, said Jon Norris, a managing director with HSBC. Overall, biotechs across the U.S. and Europe raised $6.8 billion in #venturecapital funding during the first three months of the year, nearly $1 billion more than the most active quarter in 2023. Venture firms are continuing to seek out surer bets, though. While some seed and Series A rounds are being built around more cutting-edge technology, many more are for tried-and-true management teams working to improve existing platforms, like #antibody-drug conjugates or #radiopharmaceuticals. Among the most active investors currently are OrbiMed, ARCH Venture Partners, GV (Google Ventures), RA Capital Management and Cormorant Asset Management, LP, according to William Blair. Several life sciences investment firms have closed new funds in the first quarter of 2024, including TCGX, Scion Life Sciences and Goldman Sachs — a sign of industry interest. Biotech #IPOs also rebounded last quarter to pre-pandemic levels! Initial public offerings by #biotechnology companies reached pre-pandemic levels during the first quarter, with nine #drugmakers collectively raising more than $1.3 billion, according to BioPharma Dive data. The sum is more than three times the $375 million in total proceeds from biotech IPOs in the first quarter last year, and roughly matches the first quarter total in 2020. Six of the nine biotechs to price IPOs between January and March raised $100 million or more. The largest two offerings, from CG Oncology and Kyverna Therapeutics, raised $380 million and $319 million respectively.

🧬 The biotechnology sector continues to attract substantial venture capital investment. Recent data indicates that securing $100 million in a single round has become increasingly common, reflecting growing investor confidence in the industry's potential. Notably, firms like RA Capital and Arch Venture Partners have emerged as some of the most active investors in this space. 💊 At Leap Advisory and Intelligence, we recognize the critical role of strategic partnerships in navigating this evolving landscape. Our expertise lies in fostering collaborations across tech, pharma, and health systems, ensuring that innovative biotech ventures receive the support they need to thrive. 🔬 For a comprehensive overview of current biotech venture capital trends, we recommend reading BioPharma Dive's recent analysis: https://lnkd.in/guUrUTAy #Biotech #VentureCapital #Innovation #StrategicPartnerships

Biotech Venture Capital Market: Signs of a Thaw for 2024? Here's the good news: private funding for early-stage biotech startups is on the rise in the first quarter of 2024. This suggests renewed investor confidence in the sector, particularly compared to the slowdown of 2023. Key points to consider: 1) Big numbers: A significant jump in the number of companies raising over $100 million in private rounds indicates a willingness to invest in promising early-stage ventures. 2) Focus on established areas: Investors are still prioritizing "surer bets" – companies developing drugs in areas like cancer and neurology, or those with experienced management teams working on proven technologies. 3) Active investors: Established VC firms like OrbiMed and Arch Venture Partners are leading the charge, with new funds being raised by players like Goldman Sachs. This signals strong industry interest. 4) Preclinical and Phase 1 focus: Funding is flowing towards companies in the early stages of drug development, suggesting a long-term outlook from investors. 5) Return of IPO buyers and M&A rebound: Promising clinical data is still attracting interest for initial public offerings (IPOs), a positive sign for late-stage biotechs. Blockbuster deals brokered at the end of last year included AbbVie’s $8.7 billion acquisition of Cerevel Therapeutics and $10.1 billion buy of ImmunoGen, Roche’s $7.1 billion purchase of Telavant and Bristol Myers Squibb’s $14 billion deal for Karuna Therapeutics. Overall, this uptick is a welcome change from 2023, when companies struggled to secure funding and relied more on existing investors. A word of caution: While the trend is positive, some experts warn against replicating the aggressive investment pace of 2021. We need a balance between innovation and calculated risk. Stay tuned for further updates! I'm also happy to answer any specific questions you may have about the biotech investment landscape. What are your thoughts for 2024? Leave a comment below Claus Johansen Rohan Gidvani Nandita Shangari Nick Frame Jessica Davis Sam Kessel MD, MBA Tej Panesar Jacob Masters Michael Salako PhD MBA John Xue #biotech #investment #investor #vc #drug #discovery #healthcare #market #business #ipo _________________________________________________________________________________ Biotech investor or innovator? We assist investors unlock potential by assisting with due diligence and companies refine strategies for success and fundraising. Let's chat! Have you enjoyed this? Recommend Repost ♻️ if you find it useful Follow me, hit the 🔔 Adrian Rubstein

Venture investing in biotech: what makes it unique In this article, our managing partner, Bibhash Mukhopadhyay, provides insights into the what makes biotech investing a specialists’ game and an unique blend of science and art! He emphasizes the need for deep technical expertise to know what and when to do specific investments, as well as patience, discipline and industry-specific expertise to know when to exit them. Want to learn more about the art of biotech venture capital? Check out Bibhash's full piece from European Biopharmaceutical Review, Autumn 2024, pages 65-68. © Samedan Ltd https://lnkd.in/dm2WbQzb #biotech #venturecapital #investment #innovation #SoundBioventures

In the first half of 2024, more than 50 biotech companies raised venture rounds of $100 million or more. If this pace continues, we will be approaching market conditions seen during the peak around three years ago. Take a closer look at our latest life sciences research ⬇️ ▪️ A few factors are driving this push to mega funding rounds. Most prominently, rather than focusing on the early-stage investments popular in the boomtimes of 2020 and 2021, investors are interested in companies that are well into trials with strong clinical data, as they are seen as less risky relative to discovery stage companies. ▪️ Most notable, Xaira Therapeutics out of the Bay Area, announced it raised $1 billion in April to fuel its research in drug discovery with help of artificial intelligence making it one of the largest biotech venture deals ever. ▪️ While a great deal of the capital raises will be used to grow operations and support research, over the past year plus we’ve seen several cases where mega raises have translated into a real estate transaction. In March 2023, Cargo Therapeutics raised $200 million – nine months later they signed for a 99,000 s.f. deal in Mid-Peninsula in the Bay Area. Also located in the Mid-Peninsula, Terremoto Biosciences signed a lease for 27,000 s.f. earlier this year after raising $175 million in November 2023.

As evidenced by the trends in Series A financings, start-ups have been facing challenges in securing funding. If you're interested in learning more about the funding environment for first-time rounds in 2023, check out this update from Citeline Commercial https://lnkd.in/exM7wPZT #biotech #pharma #seriesA #startup #venturecapital

🟣It's time for our Capital Movers radar! Who’s shaping the next big thing in the biotechnology industry? Check out the top 10 most active investors of the year: ⤵️ 1️⃣ RA Capital Management Based in the US and founded in 2004 by Peter Kolchinsky, RA Capital Management invests in drug development, medical devices, diagnostics, and research tools. ➡️ # rounds: 34 2️⃣ Alexandria Venture Investments (Alexandria Real Estate Equities, Inc.) Based in the US and founded in 1996, Alexandria Venture Investments focuses on early and growth stages in biotech, medical, and pharmaceutical fields across North America. ➡️ # rounds: 22 3️⃣ OrbiMed Based in the US and founded in 1998 by Sven Borho and Carl Gordon, OrbiMed focuses on biopharmaceuticals, medical devices, and healthcare services. ➡️ # rounds: 20 4️⃣ Forbion Based in the Netherlands and founded in 2006 by Sander Slootweg and Geert-Jan Mulder, Forbion bridges research and development, leveraging expertise in drug development and company building. ➡️ # rounds: 18 5️⃣ The Invus Group Based in the US and founded in 1985 by Ray Debbane, Invus invests in early-stage growth companies across various sectors, including biotechnology. ➡️ # rounds: 16 6️⃣ ARCH Venture Partners Based in the US and founded in 1986 by Steven Lazarus, Clinton Bybee, Keith Crandell and Robert Nelsen, ARCH Venture Partners focuses on early-stage investments in advanced technology companies. ➡️ # rounds: 15 7️⃣ GV (Google Ventures) Based in the US and founded in 2009 by Bill Maris, GV invests in many sectors including mobile, internet, data, science, and healthcare, among others. ➡️ # rounds: 15 8️⃣ Khosla Ventures Based in the US and founded in 2004 by Vinod Khosla, Khosla Ventures invests in North American companies in the mobile, internet, alternative energy, storage, and materials sectors. ➡️ # rounds: 15 9️⃣ Cormorant Asset Management, LP Based in the US and founded in 2013 by Bihua Chen, Cormorant Asset Management focuses on the global healthcare sector and provides investment management services to hedge funds and private equity vehicles. ➡️ # rounds: 14 🔟 Novo Holdings Based in Denmark and founded in 1999 by Nigel Morris and Frank Rotman, Novo Holdings invests across wide range of industries such as healthcare and food. ➡️ # rounds: 13 ____________________________________________________________________________________ 🟣 Subscribe to our newsletter for an in-depth analysis of the biotechnology industry - a breakdown of key deal drivers. Also, we regularly showcase the latest deals shaping private markets. Be the first to know what’s driving the industry! 🏎️ 🟣 Need deeper insights into private markets? Request a demo today to see how DealPotential - a data sourcing and investment intelligence SaaS solution - can help you to efficiently discover, evaluate, and analyze investment opportunities. #dealpotential #PrivateMarkets #Investment